SCHEMBL565450

SCHEMBL565450

CC(C)CN(Cc1cc(Cl)c2c(c1)CCCCO2)C(=O)C1CN(Cc2cccc3c2ccn3C)CCO1

nearest known ligand 0.58

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
PROKR2 Q8NFJ6 5/20 0.58
ACKR3 P25106 1/20 0.33
SMN1; SMN2 Q16637 4/20 0.32
ALDH1A1 P00352 3/20 0.32
KDM4E B2RXH2 2/20 0.32
HPGD P15428 1/20 0.32
HSD17B10 Q99714 1/20 0.32
GRN P28799 1/20 0.32
SORT1 Q99523 1/20 0.32
HTR6 P50406 1/20 0.31
MAPT P10636 3/20 0.31
GAA P10253 2/20 0.31
MAPK1 P28482 2/20 0.31
TDP1 Q9NUW8 1/20 0.31
GRIN2B Q13224 1/20 0.30
LMNA P02545 1/20 0.30
HTT P42858 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL565197 0.91 PROKR2 (0.70) PROKR2ACKR3SMN1; SMN2ALDH1A1KDM4E
SCHEMBL10107392 0.90 PROKR2 (0.58) PROKR2ACKR3SMN1; SMN2ALDH1A1KDM4E
SCHEMBL565150 0.90 PROKR2 (0.58) PROKR2ACKR3SMN1; SMN2ALDH1A1KDM4E
SCHEMBL564992 0.89 PROKR2 (0.58) PROKR2SMN1; SMN2ALDH1A1KDM4EMAPT
SCHEMBL565926 0.89 PROKR2 (0.58) PROKR2ACKR3SMN1; SMN2ALDH1A1KDM4E
SCHEMBL10107432 0.89 PROKR2 (0.58) PROKR2SMN1; SMN2ALDH1A1KDM4EMAPT
SCHEMBL564948 0.87 PROKR2 (0.65) PROKR2ACKR3SMN1; SMN2ALDH1A1KDM4E
SCHEMBL10107420 0.86 PROKR2 (0.63) PROKR2SMN1; SMN2KDM4EGRNSORT1
SCHEMBL10119949 0.86 PROKR2 (0.63) PROKR2SMN1; SMN2KDM4EGRNSORT1
SCHEMBL10107400 0.84 PROKR2 (0.61) PROKR2ACKR3SMN1; SMN2ALDH1A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8722896-B2 Prokineticin receptor antagonists and uses thereof THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2014-05-13 US disclosed
US-8722896-B2 Prokineticin receptor antagonists and uses thereof THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2014-05-13 US disclosed
US-8722896-B2 Prokineticin receptor antagonists and uses thereof THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2014-05-13 US disclosed
US-20120035149-A1 Prokineticin Receptor Antagonists And Uses Thereof THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2012-02-09 US disclosed
US-20120035149-A1 Prokineticin Receptor Antagonists And Uses Thereof THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2012-02-09 US disclosed
US-20120035149-A1 Prokineticin Receptor Antagonists And Uses Thereof THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2012-02-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120035149-A1 Prokineticin Receptor Antagonists And Uses Thereof PROKR2, PROKR1, GIPR PROKR2 1/4885ACKR3 411/4885SMN1; SMN2 2106/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.